Andere talen Arcturus Therapeutics Holdings Inc.

Aandelen

ARCT

US03969T1097

Beurs gesloten - Nasdaq Andere beurzen 22:00:05 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
27,91 ^USD	+3,14%		-7,37%	-11,48%

27/03	Arcturus Therapeutics Holdings Insider verkocht aandelen ter waarde van $610.574, volgens een recente SEC filing	MT
21/03	Insider van Arcturus Therapeutics Holdings verkocht aandelen ter waarde van $299.839, volgens een recent SEC-document	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	27/03
Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	21/03
Arcturus Therapeutics : Positive Results of Phase III Study of Bivalent Version of Kostaive®, Self-Amplifying mRNA Vaccine Against COVID-19 (Ancestral Strain and Omicron BA.4/5), for Booster Vaccination Conducted in Japan - Form 8-K	19/03
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops	07/03
Arcturus Therapeutics: Q4 Earnings Snapshot	07/03
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q4 Revenue $34M, vs. Street Est of $37.9M	07/03
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07/03
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress	07/03
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference	26/02
Arcturus Therapeutics Holdings Inc. Announces Executive Changes	23/02
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission, for ARCT-032, for the Treatment of Cystic Fibrosis	23/02
Arcturus Gets European Orphan Medicinal Product Label For ARCT-032 to Treat Cystic Fibrosis	22/02
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis	22/02
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024	20/02
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster	05/02
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster	05/02
Passport Technologies, Inc. Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA Delivery Systems	05/01
CSL and Arcturus Therapeutics ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	22/12
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	21/12
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster	21/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arcturus Therapeutics Holdings Inc.

Aandelen

ARCT

US03969T1097

Andere talen

Filters